A Daily Pill Is Changing the Outlook for Pancreatic Cancer
Patients on the pill lived about twice as long, 13.2 months compared with 6.7 months.
- Daraxonrasib is a once-daily pill that blocks RAS proteins, including the mutated KRAS that drives more than 90% of pancreatic cancers.
- In a trial of 500 people whose pancreatic cancer had spread and grown after earlier treatment, those taking daraxonrasib lived a median of 13.2 months, compared with 6.7 months on standard chemotherapy, and had fewer serious side effects.
- The U.S. FDA approved it on August 26, 2026, for adults with metastatic pancreatic cancer who have already had treatment or cannot have multi-drug chemotherapy. Health Canada worked with the FDA on the review, but the drug is not approved in Canada yet.
- Early results using the pill with chemotherapy as a first treatment are encouraging, but that study was small and had no comparison group. For now, a clinical trial is the main way patients in Canada may be able to get it, so ask your cancer team.
Daraxonrasib for pancreatic cancer is a daily pill that targets the KRAS protein. Here is what the trials found, why the newest results need context, and where the drug stands in Canada. If you are thinking about taking part, see why people join a clinical study.
Pancreatic cancer is one of the hardest cancers to treat. It is often found late, and standard chemotherapy usually buys patients only a few extra months. A new pill called daraxonrasib is starting to show evidence of changing that.
How daraxonrasib works
The drug works by going after a protein called KRAS. When KRAS mutates, it acts like a gas pedal pressed to the floor and pushes cancer cells to keep growing. Daraxonrasib is the first drug to successfully target mutated KRAS proteins, which drive more than 90 percent of pancreatic cancers. For decades, researchers thought KRAS was impossible to target.
What the main trial showed
The pill has already proven itself in a relatively large trial. In the study, 500 patients whose cancer had come back after earlier treatment were split into two groups: one got daraxonrasib, the other got standard chemotherapy. Patients on the pill lived about twice as long, 13.2 months compared with 6.7 months. Serious side effects were also less common in subjects taking the pill, compared with those on chemotherapy. The most common adverse events included dermatitis, diarrhea, mouth sores, nausea and loss of appetite. U.S. regulators approved daraxonrasib for pancreatic cancer on August 26, 2026, and the European Commission followed recently in November.
Early results as a first treatment
The latest news on daraxonrasib is about using the pill earlier, as a patient’s first treatment. In a small study of 61 newly treated patients, doctors gave daraxonrasib together with a standard two-drug chemotherapy. Tumours shrank in about 61% of patients and disappeared on scans in about 8%. About 77% of subjects followed were still alive after one year.
These numbers do require some context. Every patient in this study got the combination, so there was no comparison group. As of yet, there is no clear cut evidence on whether adding the pill to standard of care beats chemotherapy alone. A larger trial has been designed to answer that question. Shrinking tumours is encouraging, but it doesn’t always mean people live longer.
Is daraxonrasib for pancreatic cancer available in Canada?
For Canadians, the important part of this story is what happens next. Pancreatic cancer isn’t diagnosed very often here, but the Canadian Cancer Society expects it to be the third-leading cause of cancer deaths in 2026. Health Canada took part in the U.S. review of the drug, but the application may still be under review in other countries. As of now, the drug isn’t approved in Canada, so patients here can’t get it yet. Approval is only the first step; after that comes the price. One month’s supply costs $39,800 USD. At that price, provinces and private insurers will have to decide whether to cover it, and those decisions often take longer than approval itself.
Clinical trials are the fastest way in for now, and oncologists at Princess Margaret Cancer Centre are working to open trials so Canadian patients can possibly access the drug without waiting for lengthy approvals. Patients and families should ask their cancer team about trials now.
Read more on this story at Medical Daily: daraxonrasib with chemotherapy as a first treatment.
Sources and further reading
- Canadian Cancer Society: Pancreatic cancer
- Canadian Cancer Society: Pancreatic cancer statistics (2026 projections)
- Health Canada Drug Product Database (check whether a drug is approved in Canada)
- U.S. FDA: Daraxonrasib approved for metastatic pancreatic adenocarcinoma (August 2026)
- RASolute 302 trial record (NCT06625320), ClinicalTrials.gov
Common questions
Is daraxonrasib approved in Canada?
Not yet. Health Canada worked with the U.S. Food and Drug Administration (FDA) on its review, and the FDA approved the drug on August 26, 2026. It is not approved in Canada so far, so patients here cannot get it with a regular prescription. A clinical trial is currently the main way in. Ask your cancer team whether one could be right for you.
Who is daraxonrasib approved for in the United States?
Adults with metastatic pancreatic adenocarcinoma, the most common type of pancreatic cancer, who have already had at least one treatment, or who cannot have chemotherapy that combines several drugs.
How does daraxonrasib work?
It blocks RAS proteins. A mutated KRAS protein acts like a gas pedal pressed to the floor, pushing cancer cells to keep growing. Mutated KRAS drives more than 90% of pancreatic cancers. Daraxonrasib is taken as a pill once a day.
How much does daraxonrasib cost?
In the United States, one month's supply costs US$39,800. If it is approved in Canada, provinces and private insurers will each decide whether to cover it, and those decisions often take longer than approval itself.
Health research, explained once a month
New studies and plain-language articles from our health library.
Study alerts: an email only when a matching study opens. Community: our research team may contact you about studies that may fit. Join the community
Ready when you are
See which studies you may qualify for
About five minutes. Free, and no obligation to take part.



